- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07226310
De Hysterosalpingogram (HSG) Ervaring En Tubale Spasme (HEAT) Studie (HEAT)
De Hysterosalpingogram (HSG) Ervaring En Tubale Spasme (HEAT) Studie: Een Gerandomiseerd Gecontroleerd Onderzoek
The hysterosalpingogram (HSG) is the gold standard of assessing fallopian tube patency and involves the placement of a transcervical catheter to allow for instillation of radio-opaque dye into the uterine cavity and fallopian tubes which are then imaged with abdominal x-ray. A common side effect of the instillation of dye is the uterine cramping, which is both uncomfortable for the patient as well as can cause iatrogenic proximal occlusion of the fallopian tubes. Proximal tubal obstruction is often not representative of true tubal obstruction but is rather an artifact of the test. Prior studies measuring the perceived pain and cramping during HSG have been conducted which have shown reduced pain scores and decreased uterine cramping when warmed contrast dye is used. The researchers propose that the use of warmed contrast media during HSG will be correlated with decreased pain scores and fewer cases of proximal tubal occlusion in women with otherwise normal uterine anatomy.
Studie Overzicht
Gedetailleerde beschrijving
Research materials will include obtaining patient past medical history at time of the patient screening and recruitment, via utilization of Epic to search for demographic factors including age, height, weight, BMI, race/ethnicity, duration of infertility, past medical history, and gynecologic/obstetric history.
Post-procedure images from the HSG/report of the HSG findings will be saved in Epic as per usual standard clinical practice. HSG findings will be transcribed with prior demographics/history into a PHI-safe RedCap. No biospecimens will be collected under this protocol.
Patients undergoing fertility treatment that are recommended to undergo HSG as part of their evaluation will be referred to a dedicated research nurse (RN) for eligibility screening and informed consent.
Once found to be meeting inclusion criteria, the patient will be consented and scheduled for HSG as appropriate for their menstrual cycle and clinical care. Typically, patients are scheduled during cycle day 5-10 of their menstrual cycle for best study image quality.
Once scheduled, the patient will be randomized to warmed (body temperature) vs cold (room temperature) HSG. The principal investigator will create a computer-generated randomization table (1:1) using block randomization with randomly varying block size of 4 and 6 without stratification.
Study team members will have electronic access to the table of randomization within the secure REDCap randomization module and will assign each patient to a single-blinded treatment group once informed consent is obtained.
HSG will be performed in accordance with clinic policy by a physician or physician assistant trained in the procedure and interpretation of study results. Patients will be asked to complete a pre- and post-procedure questionnaire.
All data will be collected by the research team and entered into RedCap. A single study visit lasting approximately 1 hour will be conducted. The patient will be assigned a unique study ID number, and the randomization module in REDCap will be used to assign the participant to either the experimental (warm) or control (cold) group.
The patient will be blinded to the treatment allocation, but the research team will be unblinded to allow for correct choice and use of warm versus cold contrast media. As research team members will touch the HSG contrast media and be able to discern if it is cold or warm, it is impossible to maintain blinding of the research team.
The control group (cold contrast) is the current standard of care and is included in this study as a control to allow for comparison with the experimental (warm contrast) group. All patients will obtain an HSG via the same standardized technique at OURM.
Patients may withdraw from the study at any time without repercussions and will be allowed to undergo HSG with standard of care practices at OURM at their discretion. Withdrawal of participation in the study will not change the course of a patient's fertility evaluation or treatment. If the study were to end prematurely, all patients will maintain scheduled appointments for HSG with standard practice methods (cold contrast dye) to be used as per clinic protocol.
All participant recruitment and data collection activities including consenting, interventions, chart reviews, and data analysis will occur at OU Reproductive Medicine clinic (OURM) and via Epic clinical chart review as needed to obtain study data. Data analysis will be conducted in the OUHSC Department of Biostatistics and Epidemiology using data exported from the HIPAA compliant REDCap database and stored on a secure server.
Patients and their fertility provider will all be informed of their HSG results after completion of the procedure as per clinic protocol as part of their fertility evaluation. Patients will be informed of their HSG results after completion of a post-procedure pain questionnaire.
Studietype
Inschrijving (Geschat)
Fase
- Vroege fase 1
Contacten en locaties
Studiecontact
- Naam: Christy Zornes, MHR
- Telefoonnummer: 48137 (405) 271-8001
- E-mail: christy-zornes@ou.edu
Studie Locaties
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- Werving
- University of Oklahoma Health Center
-
Contact:
- Christy Zornes, MHR
- Telefoonnummer: 48137 405-271-8001
- E-mail: christy-zornes@ou.edu
-
Hoofdonderzoeker:
- LaTasha Craig, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
1. Women ages 18-45 undergoing tubal assessment via HSG.
Exclusion Criteria:
- History of fibroids
- History of pelvic inflammatory disease (PID or STD including gonorrhea, chlamydia, or trichomonas)
- History of surgically diagnosed endometriosis or suspected endometriosis on ultrasound (indicated by visualization of likely endometrioma)
- History of ectopic pregnancy or 3 or more biochemical pregnancies/pregnancy of unknown location
- History of tubal or ovarian surgery
- History of known Mullerian anomaly
- History of pelvic surgery including appendectomy
- Allergy to iodine-based contrast media
- History of prior abnormal fallopian tubes on HSG
- History of ultrasound with hydrosalpinx (unilateral or bilateral)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Cold HSG
HSG contrast will be standard, room-temperature |
|
|
Actieve vergelijker: Warm HSG
HSG constrast will be warmed. |
The intervention is warming the HSG constrast. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Post-HSG Pain Questionnaire
Tijdsspanne: Measured 1 hour after HSG procedure
|
To compare the patient experience for patients undergoing HSG when warm versus cold contrast media is utilized, patients will complete a post-HSG Questionnaire to indicate their level of pain. |
Measured 1 hour after HSG procedure
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Rate of unilateral and bilateral proximal fallopian tube occlusion
Tijdsspanne: Measured at the time of HSG procedure
|
The event proportions of unilateral and bilateral proximal fallopian tube occlusion at the time of HSG procedure will be compared between warms versus cold contrast media groups using chi-square tests or Fisher's exact tests as appropriate. |
Measured at the time of HSG procedure
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: LaTasha Craig, MD, University of Oklahoma Health Center
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 18943P
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .